Free Trial

Progyny (PGNY) Stock Price, News & Analysis

$27.10
-0.36 (-1.31%)
(As of 10:28 AM ET)
Today's Range
$26.88
$27.33
50-Day Range
$26.78
$38.15
52-Week Range
$23.90
$44.95
Volume
243,963 shs
Average Volume
918,851 shs
Market Capitalization
$2.58 billion
P/E Ratio
44.43
Dividend Yield
N/A
Price Target
$43.11

Progyny MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
57.0% Upside
$43.11 Price Target
Short Interest
Bearish
8.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Progyny in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$3.85 M Sold Last Quarter
Proj. Earnings Growth
36.23%
From $0.69 to $0.94 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.16 out of 5 stars

Medical Sector

155th out of 921 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

1st out of 8 stocks

PGNY stock logo

About Progyny Stock (NASDAQ:PGNY)

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

PGNY Stock Price History

PGNY Stock News Headlines

Progyny (NASDAQ:PGNY) Price Target Cut to $37.00
Progyny (NASDAQ:PGNY) Rating Reiterated by Cantor Fitzgerald
Progyny (NASDAQ:PGNY) PT Lowered to $30.00 at Barclays
Progyny (NASDAQ:PGNY) Cut to Sector Weight at KeyCorp
Progyny (NASDAQ:PGNY) PT Lowered to $37.00
Keybanc Downgrades Progyny (PGNY)
Why Is Progyny (PGNY) Stock Down 27% Today?
Why Is Progyny (PGNY) Stock Down 27% Today?
See More Headlines
Receive PGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
5/22/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:PGNY
Fax
N/A
Employees
563
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$43.11
High Stock Price Target
$57.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+57.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$62.04 million
Pretax Margin
6.94%

Debt

Sales & Book Value

Annual Sales
$1.09 billion
Cash Flow
$0.66 per share
Book Value
$5.77 per share

Miscellaneous

Free Float
83,509,000
Market Cap
$2.61 billion
Optionable
Optionable
Beta
1.51

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

PGNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Progyny stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PGNY shares.
View PGNY analyst ratings
or view top-rated stocks.

What is Progyny's stock price target for 2024?

10 Wall Street research analysts have issued 12 month target prices for Progyny's stock. Their PGNY share price targets range from $30.00 to $57.00. On average, they expect the company's share price to reach $43.11 in the next year. This suggests a possible upside of 57.0% from the stock's current price.
View analysts price targets for PGNY
or view top-rated stocks among Wall Street analysts.

How have PGNY shares performed in 2024?

Progyny's stock was trading at $37.18 at the beginning of 2024. Since then, PGNY stock has decreased by 26.1% and is now trading at $27.46.
View the best growth stocks for 2024 here
.

When is Progyny's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our PGNY earnings forecast
.

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) released its quarterly earnings results on Thursday, May, 9th. The company reported $0.17 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.03. The company had revenue of $278.08 million for the quarter, compared to the consensus estimate of $289.41 million. Progyny had a net margin of 5.53% and a trailing twelve-month return on equity of 11.61%. The business's revenue for the quarter was up 7.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.18 earnings per share.

What guidance has Progyny issued on next quarter's earnings?

Progyny updated its second quarter 2024 earnings guidance on Thursday, May, 9th. The company provided earnings per share guidance of 0.390-0.410 for the period, compared to the consensus estimate of 0.180. The company issued revenue guidance of $300.0 million-$310.0 million, compared to the consensus revenue estimate of $335.8 million.

What is David Schlanger's approval rating as Progyny's CEO?

25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD).

When did Progyny IPO?

Progyny (PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Who are Progyny's major shareholders?

Progyny's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.65%), Clearbridge Investments LLC (3.64%), Jennison Associates LLC (2.70%), Riverbridge Partners LLC (2.08%), Principal Financial Group Inc. (1.46%) and Baillie Gifford & Co. (1.16%). Insiders that own company stock include Cheryl Scott, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Kevin K Gordon, Mark S Livingston, Michael E Sturmer, Norman Payson, Peter Anevski, Robert Michael Floyd and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Progyny?

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PGNY) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners